WO2000076968A1 - Process for the synthesis of a-nor-seco compounds with sterane skeleton - Google Patents

Process for the synthesis of a-nor-seco compounds with sterane skeleton Download PDF

Info

Publication number
WO2000076968A1
WO2000076968A1 PCT/HU2000/000047 HU0000047W WO0076968A1 WO 2000076968 A1 WO2000076968 A1 WO 2000076968A1 HU 0000047 W HU0000047 W HU 0000047W WO 0076968 A1 WO0076968 A1 WO 0076968A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
androstane
methyl
hydroxy
seco
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2000/000047
Other languages
French (fr)
Inventor
Csaba SÁNTA
Zoltán Tuba
Sándor MAHÓ
János SZÉLES
Gábor BALOGH
János Brlik
Ferenc Trischler
Gabriella SZILÁGYI
Erika Bakcsi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Priority to AU52395/00A priority Critical patent/AU5239500A/en
Priority to EP00937109A priority patent/EP1189885B1/en
Priority to US10/030,743 priority patent/US6448413B1/en
Priority to AT00937109T priority patent/ATE246175T1/en
Priority to DE60004230T priority patent/DE60004230T2/en
Publication of WO2000076968A1 publication Critical patent/WO2000076968A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/36Oxygen atoms in position 3, e.g. adrenochrome
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/285Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with peroxy-compounds

Definitions

  • the invention relates to a new process for the synthesis of 17 ⁇ -hydroxy-17 ⁇ -methyl- l,3-seco-2-nor-5 -androstane-3-acid derivatives of formula (1)
  • R 1 and R 2 independently are C ⁇ -C alkyl or alkoxy group, hydrogen or halogen atom - which are intermediates for preparing the compounds of formula (I).
  • the 17 ⁇ -hydroxy-17 ⁇ -methyl-l,3-seco-2-nor-5 ⁇ -androstane-3-acid derivatives of formula (I) are intermediates in the synthesis of oxandrolon (17 ⁇ -hydroxy-17 ⁇ -methyl-2-oxa- 5 ⁇ -androstane-3-one), which is used as anabolic in therapy.
  • the oxandrolone is used in pediatrics and for mitigation of loss of weight developing as a consequence of infections, traumas and surgical intervention. Recently the therapeutic use was extended to the improvement of the condition of AIDS patients.
  • the reaction of mestanolone of formula (III) and aromatic nitro-aldehyde of formula (IV) is preferably carried out in methanol as C 1 -C4 alcohol in the presence of potassium hydroxide.
  • the mestanolone is preferably suspended in the mixture of the alcohol type solvent and the aqueous alkali metal hydroxide and the aromatic nitro-aldehyde of formula (IV) in alcoholic solution is added to the reaction.
  • the addition can be carried out between 0°C and the reflux temperature of the reaction mixture. The completion time of the reaction depends on the temperature.
  • the pH is checked and in case of deviation it is adjusted to the required value by addition of further alkali metal hydroxide solution.
  • the precipitated manganese dioxide is filtered off or is dissolved with the addition of a reductive agent, i.e. sodium sulfite. - 5 -
  • the pH of the solution is adjusted to 5.5-6.5 and concentrated.
  • the possible impurities precipitated from the concentrated solution are filtered off, the pH of the filtrate (which contains the desired product) is adjusted to 0-2.5 with addition of acid.
  • the precipitated product is filtered off, washed with water and dried.
  • the crude product is purified by suspending and stirring it in a halogenated alkan or in a mixture of a halogenated alkan and a ketone or in a ketone type solvent and subsequent filtration or recrystallization from a ketone type solvent.
  • the reaction is carried out the same way as in the synthesis of 17 ⁇ -hydroxy-17 ⁇ -methyl-l,3-seco-2-nor-5 ⁇ -androstane-3-acid derivative of formula (I), wherein Z is carboxyl group, with the difference that the temperature of the oxidation is 15-30°C instead of 15-40°C and 1-1.5 mol equivalent of alkali metal permanganate is used instead of 2.5-5 mol equivalent.
  • the crude product is purified by recrystallization from acetonitrile or from a ketone type solvent.
  • the oxidative cleavage of the C ⁇ - double bond of secoindoxylidene carboxylic acid derivatives of formula (II) is preferably carried out in acetone, ethanol or tertiary-butanol using sodium hydroxide as base. Both oxidation reactions are preferably carried out at 20-30°C.
  • Example 6 17 ⁇ -Hvdroxy-17 ⁇ -methyl-13-seco-2-nor-5 ⁇ -androstane-1.3-diacid 5 g (1 1.4 mmol) of crude 17 ⁇ -hydroxy-17 ⁇ -methyl-l-(1.3-dihydro-3-oxo-2H-indol-2- ylidene)-l,3-seco-2-nor-5 ⁇ -androstane-3-acid, obtained in Example 2, is dissolved in 40 cm of acetone and 0.8 g (20 mmol) of sodium hydroxide in 40 cm J of water is added. 5.4 g (34.2 mmol.
  • the filtrate is neutralized with 520 cm of 10% sulfuric acid is (pH ⁇ 6- 7), then the tertiary-butanol is evaporated at diminished pressure.
  • the residue is cooled to 18- 20°C and after 20 min stirring the precipitated crystals (the by-products of the previous and the present reaction) are filtered off and washed with 200 cm of water.
  • the filtrate is acidified with 1300 cm J of 10%) sulfuric acid (pH ⁇ 2) at 20-25°C.
  • the crystalline solution is stirred for 15 min. then filtered, washed with water and dried at 50°C till the weight is constant to yield 301 g (83.0%) of crude title compound.
  • Mp 176-190°C.
  • reaction mixture is filtered and the manganese dioxide is washed with 4.0 dm 3 of a 1 :3 mixture of tertiary-butanol-water.
  • the residue is cooled to 18-20°C and after 20 min stirring the precipitated crystals (the by-products of the previous and the present reaction) are filtered off and washed with 200 cm of water.
  • the crystalline solution is stirred for 15 min, then filtered, washed with water and dried at 50°C till the weight is constant to yield 359 g (99.0%) of crude title compound.
  • Mp 178-190°C.
  • Example 7 25 g of the crude product obtained in Example 7 is dissolved in 530 cm of acetone at reflux temperature, treated with 1.0 g of charcoal, filtered, then the filtrate is concentrated to a volume of 60 cm 3 . The concentrated mixture is cooled to 10°C and kept at this temperature for 2 h, then the precipitated crystalline product is filtered off. washed with 20 cm of cold acetone and dried to yield 20.1 g (80.4%) of the title compound. Mp: 248-250°C.
  • Example 11 17 ⁇ -Hvdro ⁇ y-17 ⁇ -methyl-l,3-seco-2-nor-5 ⁇ -androstane-l,3-diacid 3 g (6.4 mmol) of 17 ⁇ -hydroxy-17 ⁇ -methyl-l-(5-chloro-l,3-dihydro-3-oxo-2H-indol-2- ylidene)-l,3-seco-2-nor-5 ⁇ -androstane-3-acid, obtained in Example 3. is added to a stirred mixture of 0.5 g (12.5 mmol) of sodium hydroxide in 20 cm of water and 50 cm of tertiary- butanol.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention relates to a new process for the synthesis of 17β-hydroxy-17α-methyl-1,3-seco-2-nor-5α-androstane-3-acide derivatives of formula (I): wherein the meaning of Z is carboxyl or formyl group and to the new secoindoxylidene carboxylic acid derivatives of formula (II): wherein R?1 and R2¿ independently are C¿1?-C4 alkyl or alkoxy group, hydrogen or halogen atom - which are intermediates for preparing the compounds of formula (I). The 17β-hydroxy-17α-methyl-1,3-seco-2-nor-5α-audrostane-3-acid derivatives of formula (I) are intermediates in the synthesis of oxandrolon (17β-hydroxy-17α-methyl-2-oxa-5α-androstane-3-one), which is used as anabolic in therapy.

Description

Process for the synthesis of A-nor-seco compounds with sterane skeleton
The invention relates to a new process for the synthesis of 17β-hydroxy-17α-methyl- l,3-seco-2-nor-5 -androstane-3-acid derivatives of formula (1)
Figure imgf000003_0001
H
wherein the meaning of Z is carboxyl or formyl group and to the new secoindoxylidene carboxylic acid derivatives of formula (II)
Figure imgf000003_0002
- wherein R1 and R2 independently are Cι-C alkyl or alkoxy group, hydrogen or halogen atom - which are intermediates for preparing the compounds of formula (I).
The 17β-hydroxy-17α-methyl-l,3-seco-2-nor-5α-androstane-3-acid derivatives of formula (I) are intermediates in the synthesis of oxandrolon (17β-hydroxy-17α-methyl-2-oxa- 5α-androstane-3-one), which is used as anabolic in therapy. The oxandrolone is used in pediatrics and for mitigation of loss of weight developing as a consequence of infections, traumas and surgical intervention. Recently the therapeutic use was extended to the improvement of the condition of AIDS patients.
Although the 17β-hydroxy-17α-methyl-l,3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein the meaning of Z is carboxyl group, is described in the literature [J. Steroid Biochem. Molec. Bio 42(2). 229-242 (1992)] as the metabolite of oxymethalone (17β- hydroxy-2-hydroxymethylene-17α-methyl-5α-androstane-3-one) and its structure was proved by GC-MS method via a derivative of it. its synthesis and physical properties are not known. The secoindoxylidene carboxylic acid type compounds of formula (II) are new. The 17β-hydroxy-17α-methyl-l,3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein the meaning of Z is formyl group, is known, its synthesis is described in several patents, i.e. the US patents No. 3.101,349, 3,128,283 and 3,155,684, the German patent No. 1,171,425 and the French patent No. Ml 697. These patents describe the oxidation of 17β- hydroxy-17α-methyl-5α-androst-l-ene-3-one with lead tetraacetate in the presence of osmium tetroxide, when 17β-hydroxy-17α-methyl-l-oxo-l,3-seco-2-nor-5α-androstane-3-acid is obtained. The descriptions do not give yields. The use of lead tetraacetate and especially the osmium tetroxide is extremely dangerous for health and not environmental friendly. An other difficulty is. that the synthesis of the starting material, the 17β-hydroxy-17α-methyl-5α-androst- l-ene-3-one. can be carried out only in low yield by bromination of 17β-hydroxy-17α-methyl- 5 -androstane-3-one and subsequent hydrogen bromide elimination. This procedure is described i.e. in the US patent No. 3.128,283. According to the US patent No. 3.109,016 the oxidation of the above mentioned starting material is carried out by ozone in carbon tetrachloride at -20°C to yield the mixed anhydride of 17β-hydroxy-17α-methyl-l-oxo-l,3-seco-2-nor-5 -androstane-3- acid formed with formic acid. The oxidation was also carried out in dichloromethane in the presence of methanol to yield the methyl ester of the seco compound. The procedure does not give yields. As the use of carbon tetrachloride is restricted because of its harmful effect to health, the synthesis can not be used on industrial scale.
As can be seen from the state of art. despite the fact that there is a need for the compounds of formula (I), there is no such procedure for the synthesis of them, which can be carried out on industrial scale in good yield and without using dangerous reagents.
Surprisingly it was found, that the 17β-hydroxy-17 -methyl-1.3-seco-2-nor-5α- androstane-3-acid derivatives of formula (I), known only as metabolites or intermediates, can be synthesized from 17β-hydroxy-17α-methyl-5α-androstane-3-one of formula (III)
Figure imgf000005_0001
- known as mestanolone [Helv. Chim: Acta, 30(3). 867-878, (1947)] - by an industrially applicable method according to our invention as follows:
The 17β-hydroxy-17α-methyl-5α-androstane-3-one of formula (III) is reacted with an aromatic nitro-aldehyde of formula (IV)
Figure imgf000005_0002
- wherein R and R" independently are Cι-C alkyl or alkoxy group, hydrogen or halogen atom - in a C1-C4 alcohol in the presence of aqueous alkali metal hydroxide solution, the obtained secoindoxylidene carboxylic acid derivative of formula (II)
Figure imgf000005_0003
- wherein the meaning of R and R" as defined above - is separated from the reaction mixture after acidifying, in given case is recrystallized from a C1-C4 alcohol or C3-C5 ketone. and oxidized using i) for the synthesis of 17β-hydroxy-17α-methyl-1.3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein Z is carboxyl group, at 15-40°C. 2.5-5 mol equivalent, or ii) for the synthesis of 17β-hydroxy-17α-methyl-1.3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein Z is formyl group, at 15-30°C, 1-1.5 mol equivalent alkali metal permanganate in a mixture of C1-C5 alcohol or C3-C6 ketone and aqueous alkali metal hydroxide.
The reaction of mestanolone of formula (III) and aromatic nitro-aldehyde of formula (IV) is preferably carried out in methanol as C1-C4 alcohol in the presence of potassium hydroxide. The mestanolone is preferably suspended in the mixture of the alcohol type solvent and the aqueous alkali metal hydroxide and the aromatic nitro-aldehyde of formula (IV) in alcoholic solution is added to the reaction. The addition can be carried out between 0°C and the reflux temperature of the reaction mixture. The completion time of the reaction depends on the temperature.
After completion of the reaction the mixture was acidified with a diluted inorganic acid till pH = 0-2.5, diluted with water, the precipitated yellow crystals were filtered off, washed with aqueous alcohol and dried. The obtained secoindoxylidene carboxylic acid of formula (II), the substance content of which is 80-95%, is recrystallized in given case from a Cι-C alcohol or C3-
C5 ketone.
The recrystallized or the crude secoindoxylidene carboxylic acid of formula (II) is dissolved in a mixture of C1-C5 alcohol or C3-C6 ketone, water and aqueous alkali metal hydroxide solution (pH = 10-14) and for the synthesis of 17β-hydroxy-17α-methyl-l,3-seco-2- nor-5α-androstane-3-acid derivative of formula (I), wherein Z is carboxyl group, 2.5-5 mol equivalent of alkali metal permanganate in aqueous solution is added to the reaction at 15-40°C. The required temperature of 15-40°C is kept with cooling. As the reaction proceeds the mixture turns brown, due to the precipitation of the manganese dioxide. After addition of the reagent the pH is checked and in case of deviation it is adjusted to the required value by addition of further alkali metal hydroxide solution. After completion of the reaction the precipitated manganese dioxide is filtered off or is dissolved with the addition of a reductive agent, i.e. sodium sulfite. - 5 -
the pH of the solution is adjusted to 5.5-6.5 and concentrated. The possible impurities precipitated from the concentrated solution are filtered off, the pH of the filtrate (which contains the desired product) is adjusted to 0-2.5 with addition of acid. The precipitated product is filtered off, washed with water and dried. The crude product is purified by suspending and stirring it in a halogenated alkan or in a mixture of a halogenated alkan and a ketone or in a ketone type solvent and subsequent filtration or recrystallization from a ketone type solvent.
If the above mentioned oxidation step is carried out the following way, instead of 17β- hydroxy-17 -methyl-l,3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein Z is carboxyl group, the 17β-hydroxy-17α-methyl-l,3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein Z is formyl group, is obtained. The reaction is carried out the same way as in the synthesis of 17β-hydroxy-17α-methyl-l,3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein Z is carboxyl group, with the difference that the temperature of the oxidation is 15-30°C instead of 15-40°C and 1-1.5 mol equivalent of alkali metal permanganate is used instead of 2.5-5 mol equivalent. The crude product is purified by recrystallization from acetonitrile or from a ketone type solvent.
The oxidative cleavage of the Cι- double bond of secoindoxylidene carboxylic acid derivatives of formula (II) is preferably carried out in acetone, ethanol or tertiary-butanol using sodium hydroxide as base. Both oxidation reactions are preferably carried out at 20-30°C.
The procedure according to the invention is illustrated in detail by the following not limiting examples.
Example 1 17β-Hvdroxy-17α-methyl-l-(l,3-dihvdro-3-oxo-2H-indol-2-ylidene)-l,3-seco-2-nor-5α- androstane-3-acid
27.6 g (490 mmol) of potassium hydroxide in 60 cmJ of water is added to 1040 cm' of methanol, then 50 g (164.2 mmol) of mestanolone is suspended in the so obtained solution. 25 g (165.4 mmol) of 2-nitro-benzaldehyde in 210 cm3 of methanol is added to the reaction mixture over a period of 15 min. keeping the temperature at 25-30°C with cooling. After the addition of the reagent the starting material slowly dissolves and the colour of the reaction mixture turns yellow. The mixture is stirred at 20-30°C for 3 h, then checked by thin layer chromatography. After completion of the reaction it is cooled to 10-15°C and 200 cm3 (548.5 mmol) of 10% hydrochloric acid was added over a period of 15 min keeping the temperature below 20°C. During the addition of the hydrochloric acid the product starts to precipitate. Then 2500 cm of water is added to the reaction mixture and it is stirred for 30 min. The precipitated yellow- crystals are filtered off, washed with water and dried at 50°C till the weight was constant to yield 72.6 g (96%. calculated for water free compound) of crude title compound. Mp: 170-190°C. Water content: 5%. 70 g (66.5 g of water free compound) of the above crude product is recrystallized from
4760 cm3 of methanol to yield 59.36 g (89.3%, calculated for water free starting material) of crystalline product. Mp: 184-190°C. [α]D 25: +105.4° (c=l, acetone).
Example 2 173-Hvdroxy-17α-methyl-l-(l,3-dihvdro-3-oxo-2H-indol-2-ylidene)-l,3-seco-2-nor-5α- androstane-3-acid
332 g (5.92 mol) of potassium hydroxide in 730 cm3 of water is added to 9.4 dmJ of methanol, then 600 g (1.97 mol) of mestanolone is suspended in the so obtained solution. 300 g (1.98 mol) of 2-nitro-benzaldehyde in 2.4 dm of methanol is added to the reaction mixture over a period of 10 min. After the addition of the reagent the starting material slowly dissolves and the colour of the reaction mixture turns yellow. The mixture is refluxed for 1 h, then checked by thin layer chromatography. After completion of the reaction it is cooled to 15°C and 2.6 dm3 of 10% sulfuric acid is added over a period of 15-20 min keeping the temperature below 20°C. Then 24 dmJ of water is added to the reaction mixture and it is stirred for 30 min (pH=2). The precipitated yellow crystals are filtered off, washed with a 3 : 1 mixture of water and methanol and dried at 50°C till the weight was constant to yield 902.5 g (95.2%, calculated for water free compound) of crude title compound. Mp: 178-190°C. Water content: 5.3%.
Example 3 17β-Hvdroxy-17α-methyl-l-(5-chloro-l,3-dihvdro-3-oxo-2H-indol-2-ylidene)-l,3-seco-2- nor-5α-androstane-3-acid 1.6 g (28.5 mmol) of potassium hydroxide is dissolved in a mixture of 4 cm of water and 45 cm3 of methanol, then 3 g (9.85 mmol) of mestanolone is added. 2.3 g (10.5 mmol) of 5- chloro-2-nitro-benzaldehyde (technical quality, about 85%) in 25 cm3 of methanol is added to the basic reaction mixture. The mixture is stirred for 3 h, then checked by thin layer chromatography. After completion of the reaction it is cooled to 10-15°C and 12 cmJ of 10% hydrochloric acid is added, then it is diluted with 100 cmJ of water. After stirring for 20 min, the precipitated crystals are filtered off, washed with 10 cm3 of water and dried at 50°C. The obtained 4.8 g of crude product is crystallized from a mixture of dichloromethane/acetonitril to yield 3.1 g (66.7%) of the title compound. Mp: 215-217°C (decomposes).
Example 4 ^β-Hvdroxy-i^α-methyl-l^-seco^-nor-Sα-androstane-^S-diacid
5 g (1 1.4 mmol) of crude 17β-hydroxy-17α-methyl-l-(1.3-dihydro-3-oxo-2H-indol-2- ylidene)-l ,3-seco-2-nor-5α-androstane-3-acid, obtained in Example 2, is dissolved in 40 cm of aceton and 0.8 g (20 mmol) of sodium hydroxide in 40 cm3 of water is added. 2.7 g (17.1 mmol, 1.5 equivalent) of potassium permanganate in 45 cm3 of water is added to the reaction mixture over a period of 30 min, keeping the temperature at 20-30°C. After stirring for 15 min, the precipitated manganese dioxide is filtered off and washed with 40 cm3 of a 1 :3 mixture of acetone-water. The filtrate is neutralized with 5 cmJ of 10% sulfuric acid is (pH~6-7), then the acetone is evaporated at diminished pressure. The residue is cooled to 15-20°C and acidified with 12 cmJ of 10% sulfuric acid (pH~2). The crystalline solution is stirred for 20 min, then filtered, washed with water and dried at 50°C till the weight is constant to yield 1.9 g (51.6%) of the title compound. Mp: 166-173°C. Example 5
17β-Hvdroxy-l 7α-methyl-l ,3-seco-2-nor-5α-androstane-l ,3-diacid
5 g (1 1.4 mmol) of crude 17β-hydroxy-17α-methyl-l-(l,3-dihydro-3-oxo-2H-indol-2- ylidene)-l,3-seco-2-nor-5 -androstane-3-acid, obtained in Example 2, is added to a mixture of 0.8 g (20 mmol) of sodium hydroxide in 40 cm of water and 50 cm of ethanol. 5.4 g (34.2 mmol, 3.0 equivalent) of potassium permanganate in 90 cmJ of water is added to the reaction mixture over a period of 30 min, keeping the temperature at 20-30°C. After stirring for 15 min, the precipitated manganese dioxide is filtered off and washed with 40 cm" of a 1:3 mixture of ethanol -water. The filtrate is neutralized with 5 cmJ of 10% sulfuric acid is (pH~6-7), then the ethanol is evaporated at diminished pressure. The residue is cooled to 15-20°C and acidified with 12 cm3 of 10% sulfuric acid (pH~2). The crystalline solution is stirred for 20 min, then filtered, washed with water and dried at 50°C till the weight is constant to yield 2.5 g (64.6%) of crude title compound. Mp: 177.190°C.
Example 6 17β-Hvdroxy-17α-methyl-13-seco-2-nor-5α-androstane-1.3-diacid 5 g (1 1.4 mmol) of crude 17β-hydroxy-17α-methyl-l-(1.3-dihydro-3-oxo-2H-indol-2- ylidene)-l,3-seco-2-nor-5α-androstane-3-acid, obtained in Example 2, is dissolved in 40 cm of acetone and 0.8 g (20 mmol) of sodium hydroxide in 40 cmJ of water is added. 5.4 g (34.2 mmol. 3.0 equivalent) of potassium permanganate in 90 cmJ of water is added to the reaction mixture over a period of 30 min, keeping the temperature at 20-30°C. After stirring for 15 min, the precipitated manganese dioxide is filtered off and washed with 40 cm of a 1 :3 mixture of acetone-water. The filtrate is neutralized with 5 cπr of 10% sulfuric acid is (pH~6-7), then the acetone is evaporated at diminished pressure. The residue is cooled tol 5-20°C and acidified with 12 cm of 10% sulfuric acid (pH~2). The crystalline solution is stirred for 20 min, then filtered, washed with water and dried at 50°C till the weight is constant to yield 2.7 g (69.8%) of crude title compound. Mp: 176-189°C.
Example 7 17β-Hvdroxy-17α-methyl-13-seco-2-nor-5α-androstane-l,3-diacid
469.0 g of crude 17β-hydroxy-17α-methyl-l-(l,3-dihydro-3-oxo-2H-indol-2-ylidene)- l,3-seco-2-nor-5α-androstane-3-acid, obtained in Example 2, is added to a stirred mixture of 60.0 g (1.5 mol) of sodium hydroxide in 3.0 dm of water and 6.5 dm of tertiary-butanol. After dissolving the starting material the pH of the solution is checked (pH=12-13). 433 g (2.74 mol) of potassium permanganate in 7.2 dm of water is added to the reaction mixture over a period of 2 h, keeping the temperature at 20-30°C with cooling. During the addition of the reagent the reaction mixture turns dark brown and manganese dioxide precipitates. After addition of two third of the starting material 400 cm3 of 10% sodium hydroxide is added to the reaction mixture and after stirring for 5 min. the pH is checked (pH=12), then the addition of the reagent is continued. After the addition the reaction mixture is stirred for 30 min at 20-30°C. Then the reaction mixture is filtered and the manganese dioxide is washed with 4.0 dm3 of a 1 :3 mixture of tertiary-butanol-water. The filtrate is neutralized with 520 cm of 10% sulfuric acid is (pH~6- 7), then the tertiary-butanol is evaporated at diminished pressure. The residue is cooled to 18- 20°C and after 20 min stirring the precipitated crystals (the by-products of the previous and the present reaction) are filtered off and washed with 200 cm of water. The filtrate is acidified with 1300 cmJ of 10%) sulfuric acid (pH~2) at 20-25°C. The crystalline solution is stirred for 15 min. then filtered, washed with water and dried at 50°C till the weight is constant to yield 301 g (83.0%) of crude title compound. Mp: 176-190°C.
Example 8 17β-Hvdroxy-17α-methyl-1.3-seco-2-nor-5α-androstane-l,3-diacid
469 g of recrystallized 17β-hydroxy-17α-methyl-l-(l,3-dihydro-3-oxo-2H-indol-2- ylidene)-1.3-seco-2-nor-5α-androstane-3-acid, obtained in Example 1. is added to a stirred mixture of 60 g (1.50 mol) of sodium hydroxide in 3.0 dm3 of water and 6.5 dmJ of tertiary- butanol. After dissolving the starting material the pH of the solution is checked (pH=12-13). 433 g (2.74 mol) of potassium permanganate in 7.2 dmJ of water is added to the reaction mixture over a period of 2 h, keeping the temperature at 20-30°C with cooling. During the addition of the reagent the reaction mixture turns dark brow i and manganese dioxide precipitates. After addition of two third of the starting material 400 cmJ of 10% sodium hydroxide is added to the reaction mixture and after stirring for 5 min, the pH is checked (pH=12), then the addition of the reagent is continued. After the addition the reaction mixture is stirred for 30 min at 20-30°C. Then the reaction mixture is filtered and the manganese dioxide is washed with 4.0 dm3 of a 1 :3 mixture of tertiary-butanol-water. The filtrate is neutralized with 520 cmJ of 10% sulfuric acid is (pH=6), then the tertiary-butanol is evaporated at diminished pressure. The residue is cooled to 18-20°C and after 20 min stirring the precipitated crystals (the by-products of the previous and the present reaction) are filtered off and washed with 200 cm of water. The filtrate is acidified with 1300 cm3 of 10%) sulfuric acid (pH=2) at 20-25°C. The crystalline solution is stirred for 15 min, then filtered, washed with water and dried at 50°C till the weight is constant to yield 359 g (99.0%) of crude title compound. Mp: 178-190°C.
Example 9 17β-Hvdroxy-l 7α-methyl-l ,3-seco-2-nor-5α-androstane-l ,3-diacid
326 g of the crude product obtained in Example 7 is added to mixture of 2.6 dm of dichloromethane and 650 cm3 of acetone over a period of 20 min and the obtained suspension is stirred for 3 h, then filtered, washed with a mixture of 400 cm3 of dichloromethane and 100 cmJ of acetone and dried at 50°C to yield 232 g (71%) of the title compound. Mp: 249-251 °C. [α]D 25 = -18.4° (c=l, methanol).
Example 10 17β-Hvdroxy-17α-methyl-l,3-seco-2-nor-5α-androstane-l,3-diacid
25 g of the crude product obtained in Example 7 is dissolved in 530 cm of acetone at reflux temperature, treated with 1.0 g of charcoal, filtered, then the filtrate is concentrated to a volume of 60 cm3. The concentrated mixture is cooled to 10°C and kept at this temperature for 2 h, then the precipitated crystalline product is filtered off. washed with 20 cm of cold acetone and dried to yield 20.1 g (80.4%) of the title compound. Mp: 248-250°C.
Example 11 17β-Hvdroχy-17α-methyl-l,3-seco-2-nor-5α-androstane-l,3-diacid 3 g (6.4 mmol) of 17β-hydroxy-17α-methyl-l-(5-chloro-l,3-dihydro-3-oxo-2H-indol-2- ylidene)-l,3-seco-2-nor-5α-androstane-3-acid, obtained in Example 3. is added to a stirred mixture of 0.5 g (12.5 mmol) of sodium hydroxide in 20 cm of water and 50 cm of tertiary- butanol. 3.0 g (19 mmol, 3.0 equivalent) of potassium permanganate in 50 cmJ of water is added to the reaction mixture over a period of 30 min, keeping the temperature at 20-30°C. After stirring for 15 min the precipitated manganese dioxide is filtered and washed with 30 cmJ of a 1 :3 mixture of tertiary-butanol-water. The filtrate is neutralized with 3 cmJ of 10% sulfuric acid is (pH~6-7), then the tertiary-butanol is evaporated at diminished pressure. The residue is cooled to 15-20°C and acidified with 9 cm3 of 10% sulfuric acid (pH~2). The crystalline solution is stirred for 20 min, then filtered, washed with water and dried at 50°C till the weight is constant to yield 2.0 g (93.0%) of crude title compound. Mp: 178-190°C.

Claims

What we claim is:
1) The new secoindoxylidene carboxylic acid derivatives of formula (II)
Figure imgf000013_0001
- wherein R1 and R" independently are - alkyl or alkoxy group, hydrogen or halogen atom.
2) 17β-hydroxy-17α-methyl-l-(l,3-dihydro-3-oxo-2H-indol-2-ylidene)-l,3-seco-2-nor- 5α-androstane-3-acid among the compounds of formula (II).
3) 17β-hydroxy-17α-methyl-l-(5-chloro-l,3-dihydro-3-oxo-2H-indol-2-ylidene)-l,3- seco-2-nor-5α-androstane-3-acid among the compounds of formula (II).
4) Process for the synthesis of 17β-hydroxy-17 -methyl-l,3-seco-2-nor-5 -androstane- 3-acid derivatives of formula (I)
Figure imgf000013_0002
H
wherein the meaning of Z is carboxyl or formyl group - characterized by reacting the 17β- hydroxy- 17α-mefhyl-5α-androstane-3-one (mestanolone) of formula (III)
Figure imgf000014_0001
H
with an aromatic nitro-aldehyde of formula (IV)
Figure imgf000014_0002
- wherein R and R independently are C]-C4 alkyl or alkoxy group, hydrogen or halogen atom in a C]-C4 alcohol in the presence of aqueous alkali metal hydroxide solution, the obtained secoindoxylidene carboxylic acid derivative of formula (II)
Figure imgf000014_0003
wherein the meaning of R and R~ as defined above - is separated from the reaction mixture after acidifying, in given case is recrystallized from a C1-C4 alcohol or C3-C5 ketone and oxidized using i) for the synthesis of 17β-hydroxy-17α-methyl-l ,3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein Z is carboxyl group, at 15-40°C, 2.5-5 mol equivalent, or ii) for the synthesis of 17β-hydroxy-17α-methyl-l,3-seco-2-nor-5α-androstane-3-acid derivative of formula (I), wherein Z is formyl group, at 15-30°C, 1-1.5 mol equivalent alkali metal permanganate in a mixture of C1-C5 alcohol or C3-C6 ketone and aqueous alkali metal hydroxide.
5) The process in claim 4, characterized by reacting the 17β-hydroxy-17α-methyl- mefhyl-5α-androstane-3-one of formula (III) and the aromatic aldehyde of formula (IV) - wherein the meaning of R1 and R2 as defined above - in a mixture of methanol and aqueous potassium hydroxide. 6) The process in claim 4. characterized by using 2-nitro-benzaldehyde as aromatic aldehyde of formula (IV).
7) The process in claim 4, characterized by using 5-chloro-2-nitro-benzaldehyde as aromatic aldehyde of formula (IV).
8) The process in claim 4, characterized by carrying out the oxidation of secoindoxylidene carboxylic acid derivatives of formula (II) - wherein the meaning of R1 and R" as defined in claim 4 - in a mixture of acetone and aqueous sodium hydroxide.
9) The process in claim 4, characterized by carrying out the oxidation of secoindoxylidene carboxylic acid derivatives of formula (II) - wherein the meaning of R1 and R~ as defined in claim 4 - in a mixture of ethanol and aqueous sodium hydroxide. 10) The process in claim 4, characterized by carrying out the oxidation of secoindoxylidene carboxylic acid derivatives of formula (II) - wherein the meaning of R1 and R~ as defined in claim 4 - in a mixture of tertiary-butanol and aqueous sodium hydroxide.
11) The process in claim 1-4, characterized by carrying out the oxidation of secoindoxylidene carboxylic acid derivatives of formula (II) - wherein the meaning of R and R" as defined in claim 4 - with potassium permanganate.
PCT/HU2000/000047 1999-06-10 2000-05-26 Process for the synthesis of a-nor-seco compounds with sterane skeleton Ceased WO2000076968A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU52395/00A AU5239500A (en) 1999-06-10 2000-05-26 Process for the synthesis of a-nor-seco compounds with sterane skeleton
EP00937109A EP1189885B1 (en) 1999-06-10 2000-05-26 Process for the synthesis of a-nor-seco compounds with sterane skeleton
US10/030,743 US6448413B1 (en) 1999-06-10 2000-05-26 Process for the synthesis of a-nor-seco compounds with sterane skeleton
AT00937109T ATE246175T1 (en) 1999-06-10 2000-05-26 METHOD FOR PRODUCING A-NOR-SECO COMPOUNDS WITH STERAN SKELETON
DE60004230T DE60004230T2 (en) 1999-06-10 2000-05-26 METHOD FOR PRODUCING A-NOR-SECO CONNECTIONS WITH STERANE SKELETON

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP9901939 1999-06-10
HU9901939A HU224816B1 (en) 1999-06-10 1999-06-10 Process for producing a-nor-seco-steroide compounds, seco-indoxylidenecarboxilicacid derivetives as intermediates thereof

Publications (1)

Publication Number Publication Date
WO2000076968A1 true WO2000076968A1 (en) 2000-12-21

Family

ID=89998479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2000/000047 Ceased WO2000076968A1 (en) 1999-06-10 2000-05-26 Process for the synthesis of a-nor-seco compounds with sterane skeleton

Country Status (8)

Country Link
US (1) US6448413B1 (en)
EP (1) EP1189885B1 (en)
AT (1) ATE246175T1 (en)
AU (1) AU5239500A (en)
DE (1) DE60004230T2 (en)
ES (1) ES2203483T3 (en)
HU (1) HU224816B1 (en)
WO (1) WO2000076968A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6820256B2 (en) * 2000-12-13 2004-11-16 Microsoft Corporation System and method for whole-system program analysis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128283A (en) * 1961-05-10 1964-04-07 Searle & Co 17-oxygenated oxa-steroids and intermediates thereto

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3280133A (en) * 1964-10-12 1966-10-18 Searle & Co (optionally alkylated)-2-aza-5alpha-androstan-17beta-ols and acyl derivatives thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128283A (en) * 1961-05-10 1964-04-07 Searle & Co 17-oxygenated oxa-steroids and intermediates thereto

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 117, no. 3, 20 July 1992, Columbus, Ohio, US; abstract no. 20715z, BI, HONGGANG ET AL.: "Studies on anabolic steroids-8. GC/MS characterization of unusual seco acidic metabolites of oxymetholone in human urine." XP002149884 *
DATABASE CHEMICAL ABSTRACTS XP002149885 *
J. STEROID BIOCHEM. MOL. BIOCHEM., vol. 42, no. 2, - 1992, pages 229 - 242 *

Also Published As

Publication number Publication date
HU224816B1 (en) 2006-02-28
DE60004230T2 (en) 2004-05-27
AU5239500A (en) 2001-01-02
ES2203483T3 (en) 2004-04-16
EP1189885B1 (en) 2003-07-30
US6448413B1 (en) 2002-09-10
DE60004230D1 (en) 2003-09-04
ATE246175T1 (en) 2003-08-15
EP1189885A1 (en) 2002-03-27
HU9901939D0 (en) 1999-08-30
HUP9901939A2 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
CA1161848A (en) Substituted indoline-2-one derivatives
US4316020A (en) Preparation of isatoic anhydrides
US4978773A (en) Process for the preparation of 2,6-dichlorodiphenylaminoacetic acid derivatives
EP1189885B1 (en) Process for the synthesis of a-nor-seco compounds with sterane skeleton
US4313000A (en) Process for preparing 5-(2-chloro-4-trifluoromethylphenoxy)-2-nitro-N-alkanesulphonyl benzamides from a toluene derivative and intermediates
HU185378B (en) Process for producing 7-alkoxy-carbonyl-6,8-dimethyl-4-hydroxy-methyl-1-phtalazones
CN101815709B (en) The manufacture method of dibenzo oxa-* compound
EP1189925B1 (en) New process for the synthesis of 17beta-hydroxy-17alpha-methyl-2-oxa-5alpha-androstane-3-one
US6384217B1 (en) 5-cyano-10-hydroxy-10,11-dihydro-5h-dibenz[b,f]azepine, the processes for its preparation and for its conversion into 5-carbamoyl-10-oxo-10, 11-dihydro-5h-dibenz[b,f]azepine or into 5-carbamoyl-5h-dibenz[b,f]azepine
SU1124886A3 (en) Method of obtaining quinolines
JPH09268186A (en) Method for producing 4-chromanones
NO309600B1 (en) Improved process for the preparation of 4-hydroxy-2-pyrrolidone
HU196381B (en) Process for preparing 8-halogen-5,6-dialkoxy-quinazolin-2,4-dione derivatives
EP0052959B1 (en) Production of purine derivatives and intermediates therefor
US4751314A (en) Preparation of tetrachloro-3-iminoisoindolin-1-one
SU262906A1 (en) METHOD OF OBTAINING INDOL PRODUCTION
JP3976286B2 (en) Method for producing 2-benzoyl-cyclic 1,3-diketone derivative
US4024136A (en) Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide
US3347864A (en) Production of aminoquinolines
US5124459A (en) Process for the preparation of 3-(3-pyridyl)-1H,3H-pyrrolo[1,2-c]thiazole-7-carbonitrile
CZ291601B6 (en) Process for preparing formyl imidazoles
JP4075342B2 (en) Process for producing 4,5-disubstituted-1,2,3-triazole
PL123691B1 (en) Process for preparing derivatives of pyrimido/1,2-a/azepines
EP0359474A1 (en) Pyridazinone manufacture
KR800000408B1 (en) Method for producing 4-hydroxy-2H-naphtho [2, 1-e] -1, 2-thiazine-3-carboxamide-1, 1-dioxides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10030743

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000937109

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000937109

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000937109

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP